GenFleet Therapeutics
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1206 Zhangjiang Rd Bldg A, Shanghai, Sha...Phone Number
+86 2168821388Website
www.genfleet.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About GenFleet Therapeutics
Founded in 2017, GenFleet Therapeutics is a China-based R&D biotech company pursuing innovative therapeutic molecules–small and large. The company is headquartered in Pudong District, Shanghai, China.Explore more
GenFleet Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GenFleet Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if GenFleet Therapeutics had a recent Job posting/layoffs
GenFleet Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if GenFleet Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if GenFleet Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when GenFleet Therapeutics launches new products
Earning: See what the market has to say on GenFleet Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once GenFleet Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at GenFleet Therapeutics
Recommended Actions
Find VP level buyers at GenFleet Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
GenFleet Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GenFleet Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GenFleet Therapeutics.
GenFleet Therapeutics financials insights
Gather financial insights about GenFleet Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$17M
2021
Series B
$16M
Series C
$75M
GenFleet Therapeutics Tech Stack
A closer look at the technologies used by GenFleet Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
GenFleet Therapeutics News & Media
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. G12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-taGenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination...GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a multi-center, open-label, randomized and controlled phase III study treating refractory metastatic colorectal cancer (CRC) patients. It is the first phase III trial of KRAS G12C inhibitor monotherapy targetinGenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at the 2024 American Association for Cancer Research (AACR) Annual Meeting. GFH547 is developed with novel mechanism of action by reshaping and repurposing intracellular cyclophilin A (CypA) protein to targ
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GenFleet Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, GenFleet Therapeutics is a China-based R&D biotech company pursuing innovative therapeutic molecules–small and large. The company is headquartered in Pudong District, Shanghai, China.... Read More
